DPR Construction’s Post

    In the words of renowned investor Peter Lynch, “Know what you own, and know why you own it”, we delve into the investment rationale of Thermo Fisher Scientific.   As an unparalleled catalyst of innovation, Thermo Fisher plays a fundamental role in the healthcare landscape. Its state-of-the-art tools, instruments and services are essential resources for researchers and scientists, facilitating ground-breaking discoveries in fields such as medicine, genetics, and environmental science. Read the attached note for why Thermo Fisher is an attractive choice for investors seeking both long-term stability and growth potential. But beyond the financial allure, investing in Thermo Fisher aligns shareholders with a company that is contributing to resolving global healthcare challenges.  

Life science firms look for expansion through efficiency ''However, while focused on expansion, firms are aiming to achieve their objectives by increasing their efficiency and making better and smarter use of existing resources, with groundbreaking discoveries less of a priority at least in the short term. When asked about their greatest opportunities over the next two years, 47% named increasing technology and automation in production (53% Latin America) and 44% new ways of working among their top choices.'' Global Life Science Risk Report 2024: https://lnkd.in/eFFNp5CF

This week I was meeting with HGA Principal/Life Sciences Practice Leader Mark Allen, and there was a very simple ask he always uses during Life Science projects that stood out to me — "Tell me about the science." The simplest things can have the most significant impact on design. Our job is to truly understand the people, research, and science that will inhabit these spaces. This ensures each project meets the unique needs of researchers and innovators. From planning to design, our approach is built on collaboration, precision, and an unwavering dedication to excellence. Read Mark's insights on "Planning and Design Solutions for Life Sciences" here:https://lnkd.in/emHTMbNd #lifesciences #research #innovation

Key Considerations in Joint Technology Development Agreements in Life Sciences 🧪 Experts will delve into the nuances of Joint Technology Development Agreements

Key Considerations in Joint Technology Development Agreements in Life Sciences 🧪 Experts will delve into the nuances of Joint Technology Development Agreements

Key Considerations in Joint Technology Development Agreements in Life Sciences 🧪 Experts will delve into the nuances of Joint Technology Development Agreements

Key Considerations in Joint Technology Development Agreements in Life Sciences 🧪 Experts will delve into the nuances of Joint Technology Development Agreements

Synergizing Success: A Guide to Cross-Functional Collaboration in the Life Sciences Industry https://buff.ly/3SjI3xY

Are green laboratories a distant pipe dream? A cross-disciplinary group of more than 50 experts and industry leaders came up with six opportunities for lab managers to drive through #sustainable change in their operations: 1 – Optimise building energy use 2 – Promote equipment transparency 3 – Facilitate equipment upgrades 4 – Streamline lab storage and right-size equipment 5 – Implement effective waste management 6 – Enhance supply chain transparency   'Transforming to Zero: Changing Behaviours for Decarbonising Laboratories' has been developed by 3PM Project Management & 3XN/GXN, with the support of Oxford Properties Group.   The report’s contributors are reputable members of the scientific community, including Oxford Properties Group, Innovate UK, BBSRC, Leesman, The Pirbright Institute, The Institute of Cancer Research, The Francis Crick Institute, Imperial College London, UCL, University of Cambridge, British Land, Norwich Bioscience Institutes (NBI) Partnership, Norwich Research Park, GSK, ADC Therapeutics, Arup, Domainex, Multus, RFC Power, and Cryoserve Engineering Services. --- Lead Researchers: James Buckley-Walker - Kåre Stokholm Poulsgaard - Liam Brandwood Special thanks to Jason Millichamp (Lead Research Manager at UCL) and Miriam Windsor (Head of Research Services at The Pirbright Institute) for joining the panel at our launch in London and participating in this video. #decarbonisation #lifescience #netzerotargets #DeepDive ♻️ 3XN/GXN

Key Considerations in Joint Technology Development Agreements in Life Sciences 🧪 Experts will delve into the nuances of Joint Technology Development Agreements